These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 32447595)
1. Real-world evaluation of effectiveness and tolerance of chemotherapy for early-stage breast cancer in older women. Delgado-Ramos GM; Nasir SS; Wang J; Schwartzberg LS Breast Cancer Res Treat; 2020 Jul; 182(2):247-258. PubMed ID: 32447595 [TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. Nyrop KA; Deal AM; Shachar SS; Basch E; Reeve BB; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Reeder-Hayes KE; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB Oncologist; 2019 Jun; 24(6):762-771. PubMed ID: 30552158 [TBL] [Abstract][Full Text] [Related]
3. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. Conte P; Frassoldati A; Bisagni G; Brandes AA; Donadio M; Garrone O; Piacentini F; Cavanna L; Giotta F; Aieta M; Gebbia V; Molino A; Musolino A; Ferro A; Maltoni R; Danese S; Zamagni C; Rimanti A; Cagossi K; Russo A; Pronzato P; Giovanardi F; Moretti G; Lombardo L; Schirone A; Beano A; Amaducci L; Bajardi EA; Vicini R; Balduzzi S; D'Amico R; Guarneri V Ann Oncol; 2018 Dec; 29(12):2328-2333. PubMed ID: 30219886 [TBL] [Abstract][Full Text] [Related]
4. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients. Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890 [TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. Liutkauskiene S; Grizas S; Jureniene K; Suipyte J; Statnickaite A; Juozaityte E BMC Cancer; 2018 Apr; 18(1):453. PubMed ID: 29678165 [TBL] [Abstract][Full Text] [Related]
6. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. Yamashiro H; Iwata H; Masuda N; Yamamoto N; Nishimura R; Ohtani S; Sato N; Takahashi M; Kamio T; Yamazaki K; Saito T; Kato M; Lee T; Kuroi K; Takano T; Yasuno S; Morita S; Ohno S; Toi M; Breast Cancer; 2020 Jul; 27(4):631-641. PubMed ID: 32060785 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer. Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751 [TBL] [Abstract][Full Text] [Related]
8. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M; Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS; Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379 [TBL] [Abstract][Full Text] [Related]
10. Continued value of adjuvant anthracyclines as treatment for early breast cancer. Turner N; Biganzoli L; Di Leo A Lancet Oncol; 2015 Jul; 16(7):e362-9. PubMed ID: 26149888 [TBL] [Abstract][Full Text] [Related]
11. Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy. Chang H; Tao YL; Jiang W; Chen C; Liu SL; Ye WJ; Gao YH BMC Cancer; 2020 Jun; 20(1):498. PubMed ID: 32487091 [TBL] [Abstract][Full Text] [Related]
12. A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer. Parsons BM; Uprety D; Smith AL; Borgert AJ; Dietrich LL J Natl Compr Canc Netw; 2018 Nov; 16(11):1311-1320. PubMed ID: 30442732 [No Abstract] [Full Text] [Related]
13. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy. Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292 [TBL] [Abstract][Full Text] [Related]
15. Acute toxicity and tolerability of anthracycline-based chemotherapy regimens in older versus younger patients with breast cancer: real-world data. Monteiro AR; Garcia AR; Póvoa S; Soares RF; Macedo F; Pereira TC; Domingues I; Pazos I; Sousa G Support Care Cancer; 2021 May; 29(5):2347-2353. PubMed ID: 32918130 [TBL] [Abstract][Full Text] [Related]
16. Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Hurria A; Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Howard J; Hudis C Drugs Aging; 2005; 22(9):785-91. PubMed ID: 16156682 [TBL] [Abstract][Full Text] [Related]
17. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter T Ann Oncol; 2008 Sep; 19(9):1530-9. PubMed ID: 18480068 [TBL] [Abstract][Full Text] [Related]
18. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963 [TBL] [Abstract][Full Text] [Related]
19. Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer. Ladwa R; Kalas T; Pathmanathan S; Woodward N; Wyld D; Sanmugarajah J Clin Breast Cancer; 2018 Oct; 18(5):e1181-e1187. PubMed ID: 29778788 [TBL] [Abstract][Full Text] [Related]
20. Patterns of on-treatment cardiac adverse events within three clinical trials of adjuvant anthracycline-based chemotherapy. Abdel-Rahman O Breast Cancer; 2018 Nov; 25(6):723-728. PubMed ID: 29882200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]